2008
DOI: 10.1016/s1262-3636(08)74600-7
|View full text |Cite
|
Sign up to set email alerts
|

Insulin resistance and steatosis in humans

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
81
0
3

Year Published

2009
2009
2015
2015

Publication Types

Select...
6
2
2

Relationship

0
10

Authors

Journals

citations
Cited by 110 publications
(84 citation statements)
references
References 38 publications
0
81
0
3
Order By: Relevance
“…These findings indicate that rats raised on an SP diet for 14 weeks have already acquired defective insulin signaling. Insulin is a strong activator of the lipogenic pathway through the activation of lipogenic transcription factors such as SREBF1 and ChREBP (Capeau 2008). In this study, we showed that SREBF1 and ChREBP levels in SP rats are markedly increased compared with those in CP rats.…”
Section: Discussionmentioning
confidence: 49%
“…These findings indicate that rats raised on an SP diet for 14 weeks have already acquired defective insulin signaling. Insulin is a strong activator of the lipogenic pathway through the activation of lipogenic transcription factors such as SREBF1 and ChREBP (Capeau 2008). In this study, we showed that SREBF1 and ChREBP levels in SP rats are markedly increased compared with those in CP rats.…”
Section: Discussionmentioning
confidence: 49%
“…Recent studies focused on the possible link between psoriasis, obesity and metabolic syndrome, which are known risk factors for NAFLD [44] . It is known that, after the age of 40 years, the psoriatic patients have a higher prevalence of metabolic syndrome and an increased risk for the each components of MetS than controls [11] .…”
Section: Psoriasis and Nafld: Epidemiologymentioning
confidence: 99%
“…These disease states are linked by the presence of hepatic steatosis or steatohepatitis with hepatic insulin resistance, endoplasmic reticulum (ER) stress, and increased generation of cytotoxic sphingolipids, including ceramides (de la Monte, Tong et al 2006;Lester-Coll, Rivera et al 2006;Moroz, Tong et al 2008;Lyn-Cook, Lawton et al 2009;Tong, Neusner et al 2009;Tong, Longato et al 2010). Mechanistically, inflammation, superimposed on disease states that promote lipid storage in hepatocytes, results in progressive ER stress, oxidative damage, mitochondrial dysfunction, and lipid peroxidation, which together promote hepatic insulin resistance (Capeau 2008;Kraegen and Cooney 2008). Hepatic insulin resistance stimulates lipolysis (Kao, Youson et al 1999), and lipolysis leads to increased generation of toxic lipids e.g.…”
Section: Neurotoxic Lipids and Neurodegenerationmentioning
confidence: 99%